MYRIAD GENETICS INC (NASDAQ: MYGN)

MYRIAD GENETICS INC

NASDAQ: MYGN (Myriad Genetics, Inc.)

Last update: 06 Mar, 8:10AM

5.13

-0.15 (-2.84%)

Add to watchlist

Previous Close	5.28
Open	5.11
Volume	1,508,369
Avg. Volume (3M)	1,157,966
Market Cap	479,696,928

Price / Earnings (Forward)	46.08
Price / Sales	0.520
Price / Book	1.18

52 Weeks Range	3.76 (-26%) — 11.44 (123%)
Earnings Date	5 May 2026

Market Trend

		Short Term	Medium Term
Industry	Diagnostics & Research (US)	Mixed	Bullish
	Diagnostics & Research (Global)	Mixed	Bullish
Stock	Myriad Genetics, Inc.	Bearish	Bearish

AIStockmoo Score

-0.7

Analyst Consensus	-0.5
Insider Activity	-2.0
Price Volatility	-2.0
Technical Moving Averages	1.5
Technical Oscillators	-0.5
Average	-0.70

Similar Stocks

Stock	Market Cap	DY	P/E (TTM)	P/B
MYGN	480 M	-	-	1.18
OPK	949 M	-	-	0.710
PSNL	703 M	-	-	2.91
FLGT	436 M	-	-	0.440
PRE	266 M	-	-	2.01
MDXH	171 M	-	-	-

Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual’s risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
Sector	Healthcare
Industry	Diagnostics & Research
Investment Style	Small Value
% Held by Insiders	2.77%
% Held by Institutions	104.21%

Ownership

Name	Date	Shares Held
Camber Capital Management Lp	30 Jun 2025	2,000,000

52 Weeks Range	3.76 (-26%) — 11.44 (123%)
Price Target Range	0.000 (-100%) — 6.00 (16%)
High	6.00 (Wells Fargo, 16.96%)	Hold
	6.00 (UBS, 16.96%)	Hold
Median	6.00 (16.96%)
Average	6.00 (16.96%)
Total	2 Hold
Avg. Price @ Call	4.43

Firm	Date	Target Price	Call	Price @ Call
UBS	24 Feb 2026	6.00 (16.96%)	Hold	4.43
Wells Fargo	24 Feb 2026	6.00 (16.96%)	Hold	4.43

Name	Avg. Buy ($)	Avg. Sell ($)	Net Quantity	Net Value ($)
DONNELLY BRIAN J	4.85	-	226,804	1,099,999
FOX JENNIFER LYNNE	4.85	4.66	189,881	922,062
HAAS KEVIN RICHARD	-	4.66	-22,310	-103,965
MUZZEY DALE	4.85	4.66	135,397	663,857
RAHA SAMRAAT S.	4.85	4.66	571,437	2,780,422
SOLAIMAN SHEREEN	4.85	4.66	158,513	771,578
VERRATTI MARK	4.85	4.66	218,134	1,063,515
WHEELER BENJAMIN RICHARD	4.85	4.66	201,434	977,858
Aggregate Net Quantity				1,679,290
Aggregate Net Value ($)				8,175,327
Aggregate Avg. Buy ($)				4.85
Aggregate Avg. Sell ($)				4.66

Name	Holder	Date	Type	Quantity	Price	Value ($)
WHEELER BENJAMIN RICHARD	Officer	15 Mar 2026	Disposed (-)	3,069	4.66	14,302
VERRATTI MARK	Officer	15 Mar 2026	Disposed (-)	14,707	4.66	68,535
MUZZEY DALE	Officer	15 Mar 2026	Disposed (-)	16,732	4.66	77,971
HAAS KEVIN RICHARD	Officer	15 Mar 2026	Disposed (-)	11,737	4.66	54,694
RAHA SAMRAAT S.	Officer	14 Mar 2026	Disposed (-)	10,816	4.66	50,403
WHEELER BENJAMIN RICHARD	Officer	14 Mar 2026	Disposed (-)	1,097	4.66	5,112
VERRATTI MARK	Officer	14 Mar 2026	Disposed (-)	5,418	4.66	25,248
SOLAIMAN SHEREEN	Officer	14 Mar 2026	Disposed (-)	5,784	4.66	26,953
MUZZEY DALE	Officer	14 Mar 2026	Disposed (-)	8,288	4.66	38,622
HAAS KEVIN RICHARD	Officer	14 Mar 2026	Disposed (-)	4,161	4.66	19,390
RAHA SAMRAAT S.	Officer	13 Mar 2026	Disposed (-)	36,304	4.66	169,177
WHEELER BENJAMIN RICHARD	Officer	13 Mar 2026	Disposed (-)	586	4.66	2,731
VERRATTI MARK	Officer	13 Mar 2026	Disposed (-)	9,164	4.66	42,704
FOX JENNIFER LYNNE	Officer	13 Mar 2026	Disposed (-)	5,995	4.66	27,937
SOLAIMAN SHEREEN	Officer	13 Mar 2026	Disposed (-)	8,899	4.66	41,469
MUZZEY DALE	Officer	13 Mar 2026	Disposed (-)	12,779	4.66	59,550
HAAS KEVIN RICHARD	Officer	13 Mar 2026	Disposed (-)	6,412	4.66	29,880
RAHA SAMRAAT S.	Officer	12 Mar 2026	Acquired (+)	618,557	4.85	3,000,001
WHEELER BENJAMIN RICHARD	Officer	12 Mar 2026	Acquired (+)	206,186	4.85	1,000,002
DONNELLY BRIAN J	Officer	12 Mar 2026	Acquired (+)	226,804	4.85	1,099,999
VERRATTI MARK	Officer	12 Mar 2026	Acquired (+)	247,423	4.85	1,200,002
FOX JENNIFER LYNNE	Officer	12 Mar 2026	Acquired (+)	195,876	4.85	949,999
SOLAIMAN SHEREEN	Officer	12 Mar 2026	Acquired (+)	173,196	4.85	840,001
MUZZEY DALE	Officer	12 Mar 2026	Acquired (+)	173,196	4.85	840,001
Show more

Date	Type	Details
27 Jan 2026	Announcement	Myriad Advances MRD Commercialization Timeline, Bolstered by New Study Data
12 Jan 2026	Announcement	Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2025 Financial Results and Introduces Full Year 2026 Financial Guidance
05 Jan 2026	Announcement	Myriad Genetics to Present at 44th Annual J.P. Morgan Healthcare Conference

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

AI Template

Your price alert

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

Realized Profit	-
Unrealized Profit	-
Dividend Received 2026	-
Total Profit	-
Avg. Return	-
Quantity (Buy)	-
Avg. Price (Buy)	-
Quantity (Sold)	-
Avg. Price (Sold)	-

No stocks matching your criteria

Profit Margin	-12.20%
Operating Margin (TTM)	-14.80%
Diluted EPS (TTM)	-1.12
Quarterly Revenue Growth (YOY)	-3.10%

Total Debt/Equity (MRQ)	22.36%
Current Ratio (MRQ)	1.90
Operating Cash Flow (TTM)	-6.40 M
Levered Free Cash Flow (TTM)	18.68 M

Return on Assets (TTM)	-5.26%
Return on Equity (TTM)	-13.84%

Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)